Eli Lilly announced that its experimental drug Retatrutide produced an average weight loss of 28.3% in the Phase 3 TRIUMPS-1 trial, significantly outperforming Wegovy (14%) and Mounjaro (20%). Second-quarter 2026 revenue reached $23 billion, up 48% year over year, with earnings per share at $7.94. The company’s market capitalization stands at roughly $1.1 trillion, and CoinCodex analysts forecast a gradual rise to $1,365 by November 2026, with a potential peak above $2,000 by August 2027. The primary risk remains market access and reimbursement policies, which could limit the Indianapolis-based pharmaceutical group’s valuation upside.
Source: Read the original article
